Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases

A technology for bone marrow proliferation and diseases, applied in the field of imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloproliferative diseases and thrombotic diseases, can solve problems such as not recognizing the potential of anti-megakaryocytes

Inactive Publication Date: 2011-05-25
SHIRE PLC
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the disclosure does not recognize the fully isolated anti-megakaryocyte potential (decreased platelet count), which may be associated with some analogs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases
  • Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases
  • Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0040] The present invention relates to 3-substituted analogs of the established platelet reducing agent anagrelide. It was expected that a substitution at the 3-position of the anagrelide molecule would block or impede a major site of metabolism and potentially prevent the formation of the highly potent PDE III inhibitor 3-OH anagrelide, while it was unexpectedly found that a substitution at the 1-position Substitution eliminates PDE III inhibition. The compounds of the present invention retain the antimegakaryocyte properties (and thus the thrombocytopenic activity) of the parent drug molecule, but have reduced PDE III inhibitory properties and therefore have a lower potential for adverse cardiovascular and antiaggregative side effects. They also have the potential to improve the pharmacokinetic profile as a result of inhibited metabolism.

[0041] Pharmaceutically acceptable acid addition salts of certain compounds of the invention may also be prepared in conventional mann...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim 1, and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.

Description

technical field [0001] The present invention relates to the discovery of substituted analogs of the selective thrombocytopenic agent anagrelide which have a reduced potential for cardiovascular side effects and should therefore lead to improved patient compliance and safety in the treatment of myeloproliferative disorders sex. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have utility as platelet reducing agents in humans. The compounds of the present invention act by inhibiting megakaryocytopoeisis, and thus the formation of platelets. Background technique [0002] Anagrelide hydrochloride (Agrylin , Xagrid ) are novel oral imidazoquinazolines that selectively reduce platelet counts in humans and are used for this purpose in the treatment of myeloproliferative disorders (MPD), such as primary Thrombocytosis (ET), in which an increased platelet count can place a patient at increased risk for blood clots. The chemical ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/04A61K31/519A61P7/02
CPCC07D487/04A61P7/00A61P7/02A61P9/00
Inventor 伯纳德·戈尔丁理查德·富兰克林安格斯·马克莱奥德
Owner SHIRE PLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap